Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alumis Inc. (ALMS : NSDQ)

• Company Description    Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 224

• Price / Volume Information    Yesterday's Closing Price: $22.02 Daily Weekly Monthly 20 Day Moving Average: 938,215 shares Shares Outstanding: 127.49 (millions) Market Capitalization: $2,807.37 (millions) Beta: -0.31 52 Week High: $30.60 52 Week Low: $2.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.28% -19.41% 12 Week -26.55% -32.10% Year To Date 125.62% 108.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 280 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-231-6625 fax: - ir@alumis.com http://www.alumis.com

• General Corporate Information    Officers Martin Babler - President and Chief Executive Officer; Chairman of John Schroer - Chief Financial Officer Sanam Pangali - Chief Legal Officer and Corporate Secretary Patrick Machado - Director Zhengbin Yao - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 022307102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 127.49 Most Recent Split Date: (:1) Beta: -0.31 Market Capitalization: $2,807.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.95 Price/Cash Flow: - Price / Sales: 334.13 EPS Growth vs. Year Ago Period: 59.34% vs. Previous Quarter: 22.11% Sales Growth vs. Year Ago Period: -89.99% vs. Previous Quarter: -9.75% ROE 03/31/26 - -88.79 12/31/25 - -116.97 09/30/25 - -121.25 ROA 03/31/26 - -70.72 12/31/25 - -88.43 09/30/25 - -92.54 Current Ratio 03/31/26 - 7.51 12/31/25 - 4.34 09/30/25 - 6.01 Quick Ratio 03/31/26 - 7.51 12/31/25 - 4.34 09/30/25 - 6.01 Operating Margin 03/31/26 - -4,592.50 12/31/25 - -1,628.99 09/30/25 - - Net Margin 03/31/26 - -2,825.70 12/31/25 - -1,011.75 09/30/25 - - Pre-Tax Margin 03/31/26 - -2,927.59 12/31/25 - -1,047.34 09/30/25 - -1,146.94 Book Value 03/31/26 - 4.45 12/31/25 - 2.88 09/30/25 - 3.69 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©